Kolexia
Raymond Eric Oncologie médicale
Raymond Eric
Oncologie médicale
Gh Paris Site Saint Joseph
Paris, France
306 Activités
9 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Tumeurs neuroendocrines Tumeurs du pancréas Tumeurs du foie Carcinome épidermoïde Adénocarcinome Cholangiocarcinome Métastase tumorale

Collaborateurs

Voir plus
Faivre Sandrine
Faivre Sandrine
Hôpital Beaujon, Clichy, France
Dreyer Chantal
Dreyer Chantal
Gh Paris Site Saint Joseph, Paris, France
Hammel Pascal
Hammel Pascal
Hôpital Paul Brousse, Villejuif, France
Paradis Valerie
Paradis Valerie
Hôpital Beaujon, Clichy, France

Industries

Voir plus
Ipsen
3 collaboration(s)
Dernière en 2021
MSD
2 collaboration(s)
Dernière en 2023
BEIGENE
2 collaboration(s)
Dernière en 2023
Mayoly Spindler
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Management of unexpected laboratory exposure to Burkholderia pseudomallei.
Annales de biologie clinique   26 février 2024
Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances.
Molecular diagnosis & therapy   24 janvier 2024
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer: A Randomized Phase 2 Study of Ompenaclid Versus Placebo in Combination With FOLFIRI Plus Bevacizumab in Patients With Previously Treated RAS Mutant Advanced or Metastatic Colorectal Cancer
Essai Clinique (Inspirna, Inc.)   17 janvier 2024
Ezurpimtrostat, A Palmitoyl-Protein Thioesterase-1 Inhibitor, Combined with PD-1 Inhibition Provides CD8 Lymphocyte Repopulation in Hepatocellular Carcinoma.
Targeted oncology   22 décembre 2023
iMonitORL: Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Essai Clinique (Centre Hospitalier Saint Joseph Saint Luc)   27 novembre 2023
TERTIO: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: a Proof of Concept Randomized Phase II Study (TERTIO - Prodige 82)
Essai Clinique (CHU Besançon)   10 novembre 2023
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma: A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Essai Clinique (BeiGene)   10 octobre 2023
1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CN15 Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Methods for Inclusive Underwriting of Breast Cancer Risk with Machine Learning and Innovative Algorithms.
Journal of insurance medicine (New York, N.Y.)   21 septembre 2023